You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Relapsed%20hematologic%20malignancy

Showing 1 - 25 of 8,407
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

After Adoptive Transfer of Genetically Modified Cell Products

Recruiting
  • Relapsed Hematologic Malignancy
  • Refractory Hematologic Malignancy
    • Memphis, Tennessee
      St. Jude Children's Research Hospital
    Feb 6, 2023

    Multiple Myeloma, Relapsed Hematologic Malignancy Trial in Seattle (Digital Health Coaching Program, Fitbit)

    Recruiting
    • Multiple Myeloma
    • Relapsed Hematologic Malignancy
    • Digital Health Coaching Program
    • Fitbit
    • Seattle, Washington
      University of Washington
    Jul 13, 2023

    International Leukemia Target Board

    Not yet recruiting
    • Relapsed Hematologic Malignancy
    • Refractory Hematologic Malignancy
    • Advice
    • (no location specified)
    Feb 25, 2022

    Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy Trial in United States (Emavusertib, ibrutinib)

    Recruiting
    • Relapsed Hematologic Malignancy
    • Refractory Hematologic Malignancy
    • Phoenix, Arizona
    • +10 more
    Feb 1, 2023

    Relapsed Hematologic Malignancy Trial in Bergamo (donor-derived CIK cells)

    Recruiting
    • Relapsed Hematologic Malignancy
    • donor-derived CIK cells
    • Bergamo, Italy
      A O Papa Giovanni XXIII
    Dec 22, 2021

    Hematologic Malignancies Trial in Shanghai (GNC-035)

    Recruiting
    • Hematologic Malignancies
    • Guiyang, Guizhou, China
    • +3 more
    Jan 13, 2023

    AML, AML With Mutated NPM1, Hematologic Malignancy Trial (Ziftomenib, Fludarabine, Idarubicin)

    Not yet recruiting
    • AML
    • +11 more
    • (no location specified)
    Aug 14, 2023

    Advanced or Metastatic Solid Tumor, Relapsed Hematologic Malignancy Trial in France (IPPACTTO)

    Recruiting
    • Advanced or Metastatic Solid Tumor
    • Relapsed Hematologic Malignancy
    • IPPACTTO
    • Angers, France
    • +6 more
    Apr 21, 2022

    CD7+ Acute Leukemia, CD7+ Lymphoma Trial in Hangzhou (anti-CD7 CAR-T)

    Recruiting
    • CD7+ Acute Leukemia
    • CD7+ Lymphoma
    • anti-CD7 CAR-T
    • Hangzhou, Zhejiang, China
      The First Affiliated Hospital，College of Medicine, Zhejiang Univ
    Sep 18, 2022

    CB-Long-Term Safety Study (CB-LTSS)

    Enrolling by invitation
    • Lymphoma, Non-Hodgkin
    • +7 more
    • Allogeneic CAR-T therapy
    • Irvine, California
    • +3 more
    Nov 18, 2022

    Hematologic Malignancy, Large B-cell Lymphoma, Acute Lymphoblastic Leukemia Trial in Los Angeles (autologous hematopoietic stem

    Not yet recruiting
    • Hematologic Malignancy
    • +5 more
    • autologous hematopoietic stem cells added to planned CAR T
    • Los Angeles, California
      Cedars-Sinai Medical Center
    May 31, 2023

    Hematopoietic Malignancy, Relapse/Recurrence, Hematopoietic Stem Cell Transplantation Trial in Suzhou (Umbilical Cord Blood

    Recruiting
    • Hematopoietic Malignancy
    • +2 more
    • Umbilical Cord Blood Transplantation
    • Suzhou, Jiangsu, China
      The First Affiliated Hospital of Soochow university
    Nov 6, 2023

    Hematological Malignancy Trial in Houston (Fludarabine Phosphate, Cyclophosphamide, CAR.5/IL15-transduced CB-NK cells)

    Not yet recruiting
    • Hematological Malignancy
    • Fludarabine Phosphate
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    Dec 5, 2022

    Extended Analysis for Leukemia/Lymphoma Treatment

    Completed
    • Relapsed Hematologic Malignancy
    • ngFDS selected treatment
    • Vienna, Austria
      Medical University Vienna
    Feb 22, 2021

    Hematological Malignancy, Lymphoma Trial in Canton (SG2501)

    Recruiting
    • Hematological Malignancy
    • Lymphoma
    • Canton, Ohio
      Gabrail Cancer Center Research, LLC
    Aug 3, 2022

    Hematologic Malignancy, Leukemia, Lymphoma Trial in Boston (CAR-37 T cells)

    Recruiting
    • Hematologic Malignancy
    • +5 more
    • CAR-37 T cells
    • Boston, Massachusetts
      Massachusetts General Hospital Cancer Center
    Oct 28, 2021

    Solid Tumor, Hematologic Malignancy Trial in Beijing (Eliglustat, Immune checkpoint inhibitor)

    Recruiting
    • Solid Tumor
    • Hematologic Malignancy
    • Beijing, China
      Department of Biotherapeutic, Chinese PLA General Hospital
    Apr 28, 2022

    Hematologic Malignancy Trial in Tianjin (IMM01)

    Terminated
    • Hematologic Malignancy
    • Tianjin, Tianjin, China
      Chinese Academy of Medical Sciences and Peking Union Medical Col
    May 5, 2023

    Haematological Malignancy Trial in Parkville (Nivolumab Injection)

    Active, not recruiting
    • Haematological Malignancy
    • Nivolumab Injection
    • Parkville, Victoria, Australia
      Royal Melbourne Hospital
    Sep 21, 2021

    Colorectal Cancer, Hematologic Malignancy, Rectum Cancer Trial in Cleveland (Vactosertib, Fludarabine Phosphate,

    Recruiting
    • Colorectal Cancer
    • +11 more
    • Cleveland, Ohio
      University Hospitals Cleveland Medical Center, Case Comprehensiv
    Jan 18, 2023

    Acute Leukemia, Chronic Leukemia, Lymphoma Trial in Milwaukee (Nivolumab (.25 mg/kg), Tocilizumab, Nivolumab (.5 mg/kg))

    Terminated
    • Acute Leukemia
    • +3 more
    • Nivolumab (.25 mg/kg)
    • +2 more
    • Milwaukee, Wisconsin
      Froedtert Hospital and the Medical College of Wisconsin
    Oct 4, 2021

    Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Tumor Trial in

    Recruiting
    • Recurrent Acute Leukemia
    • +16 more
    • Duarte, California
      City of Hope Medical Center
    Nov 22, 2022

    Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid

    Recruiting
    • Previously Treated Myelodysplastic Syndrome
    • +3 more
    • Fludarabine Phosphate
    • +9 more
    • Chicago, Illinois
      University of Chicago Comprehensive Cancer Center
    Jan 7, 2022

    Hodgkin's Lymphoma, Lymphoid Leukemia, Lymphoma Trial in Richmond (mycophenolate mofetil, Sargramostim, Filgrastim)

    Active, not recruiting
    • Hodgkin's Lymphoma
    • +17 more
    • mycophenolate mofetil
    • +2 more
    • Richmond, Virginia
      Virginia Commonwealth University/Massey Cancer Center
    Dec 21, 2021

    Hematologic Malignancy, Acute Myeloid Leukemia, MDS Trial in Chengdu, Shenzhen (CLL1-CD33 cCAR T cells)

    Recruiting
    • Hematologic Malignancy
    • +4 more
    • CLL1-CD33 cCAR T cells
    • Chengdu, China
    • +1 more
    May 17, 2021